Saxagliptin
- Generic Name
- Saxagliptin
- Brand Names
- Kombiglyze, Komboglyze, Onglyza, Qtern, Qternmet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25N3O2
- CAS Number
- 361442-04-8
- Unique Ingredient Identifier
- 8I7IO46IVQ
- Background
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
- Indication
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
- Associated Conditions
- Type 2 Diabetes Mellitus
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT03608358
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 256
- Registration Number
- NCT03199053
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 85
- Registration Number
- NCT03169959
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
- Conditions
- Diabetes Mellitus, Type 2Impaired Fasting Glucose (IFG)Impaired Glucose Tolerance (IGT)
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 700
- Registration Number
- NCT02969798
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT02920801
- Locations
- 🇨🇳
Fang Li, Shanghai, Shanghai, China
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
- Conditions
- Heart FailureType 2 Diabetes Mellitus
- Interventions
- Drug: Placebo to match saxagliptinDrug: Placebo to match sitagliptin
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 348
- Registration Number
- NCT02917031
- Locations
- 🇺🇦
Research Site, Rivne, Ukraine
A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 15
- Registration Number
- NCT02765204
- Locations
- 🇸🇪
Dept of Medical Sciences Uppsala University Hospital, Uppsala, Sweden
Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Long Min,MD
- Target Recruit Count
- 60
- Registration Number
- NCT02742233
- Locations
- 🇨🇳
The Second Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
- Conditions
- Type 2 Diabetes MellitusInadequate Glycaemic Control
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 905
- Registration Number
- NCT02681094
- Locations
- 🇷🇺
Research Site, Vladikavkaz, Russian Federation
ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-08-14
- Target Recruit Count
- 56
- Registration Number
- NCT02613897
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.